OasisLMS

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference.

Podcast Host:

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  

Podcast Guest: 

• Sam Rosner, MD, Assistant Professor of Medicine, Thoracic Medical Oncologist, University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA